aTyr Pharma Announces Second Quarter 2018 Operating Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
aTyr Pharma (LIFE) PT Lowered to $1 at BMO Capital
August 15, 2018 7:29 AM EDTBMO Capital analyst Matthew Luchini lowered the price target on aTyr Pharma (NASDAQ: LIFE) to $1.00 (from $2.00) while maintaining a Market Perform rating.
... MoreaTyr Pharma (LIFE) Misses Q2 EPS by 2c
August 14, 2018 4:23 PM EDTaTyr Pharma (NASDAQ: LIFE) reported Q2 EPS of ($0.35), $0.02 worse than the analyst estimate of ($0.33).
We have made important advancements in the development of our lead product candidate, ATYR1923, during the recent months, said Sanjay Shukla, M.D., M.S., President and CEO of aTyr.... More
